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GENETIC DISORDERS – DEVELOPMENT
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A novel missense mutation in SLC5A2 encoding SGLT2 under-
lies autosomal-recessive renal glucosuria and aminoaciduria.
Background. Familial renal glucosuria (FRG) is an isolated
disorder of proximal tubular glucose transport, characterized by
abnormal urinary glucose excretion in the presence of normal
blood glucose levels. Generalized aminoaciduria has not gener-
ally been considered a feature of this disorder. FRG has recently
been shown to result from mutations in SLC5A2, encoding the
kidney-specific low-affinity/high-capacity Na+/glucose cotrans-
porter, SGLT2. The purpose of this study was to examine the
phenotypic and genetic characteristics of three unrelated con-
sanguineous families with FRG accompanied by aminoaciduria.
Methods. Six children with autosomal-recessive FRG and 12
unaffected family members were evaluated at the clinical and
molecular levels. DNA sequence analysis of the entire coding
sequence of SLC5A2 was performed in all affected individuals.
Haplotype analysis using four polymorphic markers flanking
SLC5A2 was performed in all study participants.
Results. All affected children were asymptomatic, but dis-
played massive glucosuria (83 to 169 g/1.73m2/day) accompa-
nied by generalized aminoaciduria. Sequence analysis in all
patients revealed a novel homozygous missense mutation in
exon 8 of SLC5A2, resulting in a lysine to arginine substitu-
tion at position 321 of SGLT2 amino acid sequence (K321R).
The mutation was confirmed by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) anal-
ysis and was found to completely cosegregate with the FRG
phenotype. Haplotype analysis is consistent with identity by
descent for the mutation. The K321 residue, presumed to be lo-
cated in the eighth transmembrane domain of SGLT2, is highly
conserved across SGLT homologues.
Conclusion. Our findings confirm that mutations in SLC5A2
result in autosomal-recessive FRG. The severe glucosuria in ho-
mozygotes for the K321R mutation highlights the importance
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of the eighth SGLT2 transmembrane domain for normal glu-
cose transport. We suggest that the generalized aminoaciduria
accompanying FRG is a consequence of the severe impairment
in glucose reabsorption, and is probably not directly related to
the SGLT2 mutation. The exact role of the aberrant glucose
transport in the pathogenesis of aminoaciduria remains to be
established.
Familial renal glucosuria (FRG) (OMIM Nos. 233100
and 182381; online, Mendelian Inheritance in Man,
http://www.ncbi.nlm.nih.gov/OMIM) is a renal tubular
disorder with an autosomal-recessive inheritance pat-
tern, characterized by abnormal urinary glucose excre-
tion in the presence of normal blood fasting glucose levels
and a normal glucose tolerance test [1–3]. Heterozygous
carriers may exhibit mild glucosuria, while massive glu-
cosuria is confined to the homozygous or compound het-
erozygous states [4]. Individuals with FRG are generally
asymptomatic, except for unusual cases in which polyuria
or hypoglycemia have been described [1, 5].
FRG is considered an isolated renal tubular disorder,
not accompanied by other proximal tubular transport
abnormalities such as hyperphosphaturia, hyperurico-
suria, aminoaciduria, low-molecular-weight (LMW) pro-
teinuria, or metabolic acidosis. The glomerular filtration
rate (GFR) in FRG is normal [1].
The tubular and cellular mechanisms involved in re-
nal glucose handling have been elucidated, and the genes
encoding transporter proteins participating in this pro-
cess have been cloned and identified [6, 7]. Glucose re-
absorption in the proximal tubule is carried out by two
distinct transporter families termed SGLT and GLUT.
SGLTs reabsorb the filtered glucose across the tubular
epithelial apical membrane. Their mechanism of action
involves secondary active transport of glucose against its
concentration gradient, coupled to sodium ion transport.
Two different SGLT isoforms, SGLT1 and SGLT2, have
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been shown to mediate tubular glucose reabsorption in
humans. The bulk (90%) of filtered glucose is reabsorbed
in the proximal convoluted tubule by SGLT2—a kidney-
specific low-affinity/high-capacity Na+/glucose cotrans-
porter. The remaining filtered glucose is reabsorbed
in the pars recta of the proximal tubule by SGLT1—
a high-affinity/low-capacity Na+/glucose cotransporter.
Glucose exits the tubular epithelial cells across the ba-
solateral membrane by facilitated diffusion, which is me-
diated by two isoforms of the GLUT transporter family,
termed GLUT1 and GLUT2, located in the proximal
straight and proximal convoluted segments, respectively.
Although SGLT1 and 2 are 59% homologous in their
amino acid sequence, they exhibit several major dif-
ferences. While SGLT2 is a glucose-specific transporter
expressed exclusively in the S1 and S2 segments of the
renal proximal tubule, SGLT1 transports glucose as well
as galactose, and is expressed both in the kidney and in
the intestine. Mutations in SGLT1 have been shown to
cause glucose-galactose malabsorption [8]. Patients with
this disorder suffer from significant gastrointestinal dys-
function, but show only mild renal glucosuria. Mutations
in GLUT2 are the cause of the Fanconi-Bickel syndrome,
a glycogen-storage disease with general proximal tubular
dysfunction [9, 10].
Based on clinical, physiologic, and molecular data,
FRG has long been postulated to result from a defect
in SGLT2 [11]. However, this hypothesis has only been
very recently confirmed by the identification of specific
mutations in SLC5A2, the gene encoding SGLT2, in pa-
tients with FRG [4, 12, 13].
SLC5A2, mapped to 16p11.2, is a member of the
solute carrier family V transporter genes whose pro-
tein products share structural and functional similarities
[14, 15]. SLC5A2 is a 7.6 kb gene containing 14 exons.
The gene product, SGLT2, is a 672 amino acid protein,
with an inferred secondary structure consisting of 14
transmembrane-spanning domains, with both the NH2
and COOH termini facing the extracellular milieu [16].
Although FRG is considered an isolated renal prox-
imal tubular transport defect, there are several reports
of a familial clinical syndrome of renal glucosuria ac-
companied by aminoaciduria, in which SGLT2 mutations
have not yet been described [3, 17–19]. Furthermore,
aminoaciduria was not reported in subjects thus far de-
scribed in whom SGLT2 mutations were detected as the
cause of FRG [4, 12, 13].
In the current study we report a novel homozygous
missense mutation in SLC5A2 as a cause for FRG in
six children from three unrelated consanguineous fam-
ilies in Northern Israel. All affected individuals exhib-
ited massive renal glucosuria as well as generalized
aminoaciduria. To the best of our knowledge, this is the
first report of an SLC5A2 mutation resulting in FRG
accompanied by aminoaciduria. Furthermore, the loca-
tion of the mutation provides additional insight into the
structure-function relationship of the gene product.
METHODS
Patients
Three unrelated consanguineous families of Israeli-
Arab descent, residing in two villages of the lower Galilee
were investigated. Six children identified as having renal
glucosuria and 12 of their close relatives were included in
the study. The pedigrees shown in Figure 1 are consistent
with an autosomal-recessive inheritance. The study was
approved by the Institutional Ethics Review Committee,
and written informed consents were obtained from all
participating individuals or their legal guardians.
Phenotype analysis
Clinical data were obtained from the patients, their par-
ents, and their care providers. All index cases and their
close relatives were screened for the presence of gluco-
suria by dipstick urinalysis. Individuals found to have
glucosuria, as well as their parents, in some cases, also
underwent further biochemical evaluation aimed to es-
timate the magnitude of glucosuria and to assess over-
all proximal renal tubular function and GFR. Serum
levels of glucose, sodium, potassium, urea, creatinine,
uric acid, calcium, phosphate and 1,25 dihydroxyvitamin
D (1,25(OH)2 vitamin D), as well as plasma pH and
bicarbonate levels were measured by standard labora-
tory techniques. Twenty-four–hour urine was collected
for analysis of glucose, sodium, potassium, creatinine,
uric acid, calcium, phosphate, amino acids and b 2 mi-
croglobulin. Urine from nontoilet-trained infants was in-
termittently collected for timed intervals of several hours
per day by using adhesive urine collection bags, and
the results were extrapolated to 24 hours. Blood and
urine levels of 22 amino acids were measured using high-
performance liquid chromatography (HPLC). Uric acid
excretion per deciliter GFR was calculated according to
the formula (Uua × Scr)/Ucr where U and S represent con-
centrations in milligrams per deciliter in urine and serum,
respectively [20]. The ratio of maximum reabsorption of
phosphate to GFR (TP/GFR) was calculated as previ-
ously described [21, 22]. There were no dietary restric-
tions at the time of the study.
Mutation analysis
Genomic DNA of all participants was extracted from
peripheral blood lymphocytes using standard methods
[23]. The complete coding sequence and exon-intron
boundaries of SLC5A2 were amplified by polymerase
chain reaction (PCR) with ReddyMix-PCR Master Mix
(ABgene Advanced Biotechnologies, Surrey, UK), us-
ing a set of 13 primer pairs as previously reported [12]
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Fig. 1. Three pedigrees of six affected chil-
dren with familial renal glucosuria. The in-
heritance of the disease is compatible with
an autosomal-recessive trait. Filled squares
(males) and circles (females) indicate affected
individuals. Arrows indicate index cases. Ro-
man capitals indicate generations. Arabic
numerals indicate serial numbers of study
participants.
except for exon 8, for which a different set of primers
was designed, based upon the sequence deposited in
GenBank (accession no. NT 024812: forward 5′-ACA
ACGGTCTAAGGCGCAGTC-3′ and reverse 5′-TTAG
GAGGGTGACGGAACTGG-3′). Cycling conditions
were 95◦C for 4 minutes, followed by 35 cycles at 95◦C
for 30 seconds, 64◦C for 30 seconds, 72◦C for 20 sec-
onds, and a final extension step at 72◦C for 5 minutes.
After purification with the QIAquick gel extraction kit
(Qiagen GmbH, Hilden, Germany), PCR fragments were
directly sequenced using the BigDye terminator sequenc-
ing system (Perkin Elmer Applied Biosystems, Warring-
ton, UK), on an ABI PRISM 3100 sequencer (Perkin
Elmer). Sequence variations were confirmed by bidirec-
tional sequencing. Direct sequencing of the entire coding
sequence of the SLC5A2 gene was performed in all six
affected individuals. Sequencing of exon 8 was performed
in all 18 study participants.
Restriction fragment length polymorphism
analysis (RFLP)
A RFLP was identified in exon 8 of SLC5A2 and was
utilized for mutation detection. Amplicons encompassing
exon 8 were digested with the endonuclease DdeI, and
electrophoresed on a 1% agarose gel.
Haplotype analysis
Haplotype analysis was performed using four polymor-
phic microsatellite markers derived from the Genome
Database (GDB) spanning the SLC5A2 locus. The fol-
lowing markers were used: D16S690, D16S685, D16S753,
and D16S3044. Genotyping of markers was performed
by PCR amplification of genomic DNA using 5′ fluores-
cently labeled primers and AmpiTaq Gold polymerase
(PE Applied Biosystems, Foster City, CA, USA). Am-
plicons were resolved on an ABI 310 sequencer system
(Perkin Elmer), and allele sizes were determined using
Genscan 3.1 and Genotyper 2.1 software (PE Applied
Biosystems).
RESULTS
Clinical and biochemical characteristics
Six affected children with renal glucosuria were iden-
tified. Glucosuria was found incidentally in three of the
children (subjects IV1, IV7, and IV13) (Fig. 1) during
the evaluation of intercurrent febrile illnesses. The other
three children (subjects IV8, IV9, and IV14) were iden-
tified during family screening for the presence of glu-
cosuria. Neither the parents nor the siblings of affected
children had detectable urinary glucose by dipstick uri-
nalysis. The age of the children at the time of presen-
tation ranged from 2 months to 9 years. There were
four males and two females. All affected children were
asymptomatic, and had no history of growth retardation,
polyuria, polydipsia, or recurrent episodes of dehydra-
tion. None had a history of neurologic abnormalities. A
thorough physical examination, including evaluation of
growth rate and psychomotor development, revealed no
abnormalities. Table 1 summarizes the phenotypic char-
acteristics of the 6 affected children. All patients had
normal blood glucose levels and normal GFRs. Daily
urinary glucose excretion ranged between 83 and 169 g/
1.73m2/day. Daily urinary glucose excretion for the father
and mother of patient IV1 (subjects III5 and III6) (Fig. 1)
were 0.07 and 0.05 g/1.73m2/day, respectively. None of the
patients exhibited manifestations of generalized proxi-
mal tubular dysfunction such as metabolic acidosis, hy-
peruricosuria, hyperphosphaturia, or LMW proteinuria
(as reflected by normal levels of urinary b 2 microglobu-
lin). Serum levels of 1,25(OH)2 vitamin D were normal in
all of the patients. However, all affected children showed
generalized, nonspecific aminoaciduria of varying sever-
ity. Levels of urinary amino acid excretion in affected chil-
dren are shown in Table 2. Although aminoaciduria in our
patients was generalized, there were some amino acids
for which normal urinary levels were found. These were
aspartic acid, alpha amino adipic acid, citrulline, methio-
nine, and tryptophan. The degree of aminoaciduria was
generally mild to moderate. There was no tendency to-
ward overexcretion of specific groups of amino acids (i.e.,
charged vs. neutral). None of the parents examined for
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Table 1. Phenotypic features in affected patients
Urinary Ratio of maximum
Urinary uric acid/dL reabsorption
glucose Plasma glomerular of phosphate to Urinary
Patient excretion bicarbonate filtration glomerular filtration b 2-microglobulin
(position g/1.73m2/24 hours mEq/L rate mg/dL rate mg/dL ng/mL Generalized
in pedigree) Agea Gender (nl < 0.32)b (nl 22 to 26) (nl < 0.57) (nl 3.4 to5.4)c (nl < 150) aminoaciduriad
IV1 3 years Male 83 25.3 0.57 4.7 54 +
IV7 1.5 years Female 101 24.3 0.14 5.0 81 +
IV8 2 months Male 95 23.7 0.49 5.1 89 +
IV9 6 months Male 114 25.1 0.41 4.9 54 +
IV13 1 year Female 124 26.7 0.39 4.8 42 +
IV14 9 years Male 169 26.8 0.35 4.7 38 +
nl, normal.
aAge at presentation.
bAccording to [2, 3].
cReference values for children aged 1 month to 12 years (according to [21]).
dSee Table 2.
urinary amino acid levels showed abnormalities. Blood
amino acid levels in all patients were normal.
Mutation analysis
Mutation analysis revealed a novel homozygous ade-
nine to guanidine transition located in exon 8 at position
962 of the SLC5A2 cDNA sequence (Fig. 2A). This muta-
tion substitutes arginine for lysine (K321R) at amino acid
321 of the transporter protein SGLT2. The same muta-
tion was found in all six affected individuals. All parents
and three of the healthy siblings carried the mutation
in a heterozygous state. The other three healthy siblings
did not carry the mutation. The K321 residue was found
to be highly conserved among the human SGLT family
members and also across SGLT homologues in multiple
nonhuman species as well (Fig. 2B).
RFLP analysis
We exploited the fact that the K321R creates a novel
recognition site for the DdeI endonuclease to develop a
PCR-RFLP assay in order to screen the affected families
and healthy controls for the mutation (Fig. 2C). Homozy-
gosity for the mutant genotype was found to cosegregate
with the disease phenotype in all affected families. The
mutation was not demonstrated in 184 chromosomes de-
rived from 92 healthy unrelated individuals, indicating
that K321R does not represent a common polymorphism.
Haplotype analysis
Haplotype analysis of SLC5A2 revealed that affected
individuals of all three families share a common homozy-
gous haplotype spanning 19.3 million bases (Mb) between
D16S690 and D16S3044 (Fig. 3). These data support a
common ancestral origin wherein the K321 mutation was
transmitted identically by descent in these three appar-
ently unrelated families with FRG.
Table 2. Urinary amino acids levels (lmol/mmol creatinine) in
affected children
Reference
Amino acid IV1 IV7 IV8 IV9 IV13 IV14 valuesa
Taurine 251 126 134 333 250 195 0–164
Aspartic acid 4 1 2 2 7 3 0–9.3
Threonine 58 22 41 39 72 47 3.1–30
Serine 144 135 260 165 215 98 9.7–64
Asparagine 97 74 116 48 35 77 0–12.1
Glutamic acid 18 10 9 14 8 12 0–9
Glutamine 192 154 217 161 123 192 9.7–64
Alpha amino adipic 4 3 4 7 9 3 0–8.0
Glycine 501 423 457 34 391 258 0–334
Alanine 217 108 202 145 82 197 7.7–60.4
Citrulline 3 0.7 2 5 2 3 0.9–12
Valine 24 18 28 32 12 20 0.8–5.6
Methionine 13 3 5 9 4 9 0.7–12.5
Isoleucine 56 6 11 113 52 24 0–7.3
Leucine 39 13 27 91 19 12 1.7–6.5
Tyrosine 38 40 73 77 69 37 2.2–16.4
Phenylalanine 55 30 39 43 71 55 1.9–11.5
Tryptophan 8 0.5 4 6 10 12 0–12
Ornithine 10 2 8 9 2 10 0.1–5.0
Lysine 121 34 136 45 64 145 0–62
Histidine 309 283 448 163 395 258 0–153
Arginine 11 6 7 7 5 6 0.9–3.6
aAccording to [24].
DISCUSSION
This study describes the identification of a novel
SLC5A2 mutation in three apparently unrelated families
with FRG and aminoaciduria. Haplotype analysis sug-
gests the existence of a common ancestor for this novel
mutation.
The first SLC5A2 mutation in FRG was described by
van den Heuvel et al [12] in a 2-year-old boy of Turkish
descent, who presented with massive glucosuria of
61.6 g/L, and neurologic deficits, which were speculated
to be related to the SGLT2 mutation. The parents of this
child were consanguineous. A nonsense homozygous mu-
tation in exon 11 of SLC5A2 was found in this child, re-
sulting in truncation of SGLT2 at residue 440. Santer et al
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Fig. 2. Mutation analysis in family members affected with familial renal glucosuria. (A) Genomic DNA sequence analysis. An A → G transition
at SLC5A2 cDNA position 962 (indicated by an arrow) results in a lysine to arginine substitution at position 321 of the SGLT2 protein (K321R).
The mutation is carried in a homozygous state by an affected individual (left panel), and in a heterozygous state by his father (middle panel).
An unaffected sibling displays a wild-type (WT) sequence (right panel). (B) Protein alignment. The K321 residue (highlighted with red color)
is conserved among the human SGLT subtypes and across SGLTs of various other species (alignment was constructed with the BCM Search
Launcher computer program provided by the Human Genome Sequencing Center, Baylor College of Medicine, http://searchlauncher.bcm.tmc.edu).
(C) Confirmation of the K321R mutation in members of family 2 by restriction fragment length polymorphism (RFLP) analysis of amplicons
encompassing exon 8 of SLC5A2. The numbers correspond to the position of individuals within the pedigree (see Fig. 1 for details). K321R creates
a novel recognition site for DNA endonuclease DdeI. Heterozygous carriers of the mutation display three fragments of 406, 240, and 166 bp length.
Affected homozygotes display two fragments of 240 bp and 166 bp length. Healthy individuals carrying the wild-type sequence display only one
406 bp fragment.
[4] have recently published an extended study describ-
ing 23 families of various geographic origins, in which at
least one index case presented with isolated renal gluco-
suria. Twenty-one different SLC5A2 mutations of various
types (i.e., missense, nonsense, frameshift, and one intron
splice site mutation) were detected in these families. Only
individuals with biallelic mutations in SLC5A2 showed
severe glucosuria (>10 g/1.73m2/day). Heterozygous car-
riers of SLC5A2 mutations had either no detectable uri-
nary glucose, or very mild glucosuria (less than 4.4 g/
1.73m2 per day). In the most recent case report by Calado
et al [13], a compound heterozygous mutation in SLC5A2
was found in a 41-year-old male who presented with renal
glucosuria of 12 g/day [13].
The novel SLC5A2 mutation found in our patients re-
sults in the substitution of arginine for lysine at amino
acid 321 of the SGLT2 protein. The fact that the K321
residue was found to be highly conserved among the hu-
man SGLT family members and across SGLTs of various
other species suggests that this position may be of par-
ticular functional importance. According to the inferred
secondary structure of SGLT2, the substituted residue
is located in the eighth transmembrane domain of the
cotransporter. Although this mutation only causes a re-
placement of one basic amino acid with another, it results
in a severe impairment of SGLT2 function, as evi-
denced by the massive glucosuria in affected individuals.
Santer et al [4] have described another SGLT2 missense
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Fig. 3. Haplotype analysis in three familial
renal glucosuria (FRG) families. Genotyping
was performed using four microsatellite poly-
morphic markers flanking SLC5A2. Filled
squares (males) and circles (females) indicate
affected individuals. Arabic numerals within
squares and circles indicate serial numbers
of study participants. The common disease-
associated haplotype is shown in boxes.
mutation in exon 8 of a double heterozygote, also involv-
ing a lysine to arginine substitution (K311R) at the eighth
transmembrane cotransporter domain. The second allele
in this individual displayed a splice site mutation at the
beginning of intron 7. This patient showed a relatively
lesser degree of glucosuria (14.6 g/1.73m2/day) as com-
pared to our patients, probably due to the less severe im-
pact of this double heterozygous combination on residual
SGLT2 function. These two different mutations in exon
8 found by Santer et al and in our current report, pro-
vide evidence that the eighth transmemebrane domain
of SGLT2 must play a crucial role in the normal function
of the cotransporter.
According to the postulated topology of SGLTs, it is
suggested that transmembrane domains 10 to 13 may play
an important role in sugar binding and translocation [4,
16, 25]; hence, it is reasonable to assume that mutations
in these domains would result in significant impairment
of SGLT2 function, leading to severe glucosuria. Indeed,
cases with extreme glucosuria (glucose excretion >100 g/
1.73m2/day) in the report of Santer et al displayed either
homozygous or double heterozygous mutations affecting
SGLT2 residues of transmemebrane domains 10 to 13.
Measurements of daily urinary glucose excretion in our
patients did reveal extreme glucosuria, comparable in its
extent to the degree that has been found in glucosuria
type O (i.e., complete absence of tubular reabsorption of
filtered glucose) [5]. The original patient with this type
of glucosuria has been recently found by Santer et al [4]
to harbor an SGLT2 frameshift mutation at residue 324,
leading to truncation of transmembranes domains 8 to
14 of the protein. The authors postulated that the severe
SGLT2 dysfunction in this patient resulted from the ab-
sence of domains 10 to 13 of the protein. However, ac-
cording to our observation, a similarly severe degree of
glucosuria may also result from a single amino acid sub-
stitution at the eighth transmembrane domain. It is pos-
sible that the absence of this domain in the patient with
glucosuria type O is what made a significant contribu-
tion to the phenotype of severe SGLT2 dysfunction. Our
findings emphasize the importance of the integrity of the
eighth transmembrane domain for normal SGLT2 func-
tion. Nevertheless, the exact effect of the various SLC5A2
mutations on glucose reabsorption by SGLT2 can only be
elucidated by means of future site-directed mutagenesis
and in vitro expression studies, which have not been suc-
cessful to date, due to difficulties in functionally express-
ing SGLT2 cRNA in standard experimental expression
systems [4, 7, 11].
All individuals affected with FRG in our study
were asymptomatic, and none of them displayed hypo-
glycemia, polyuria, or dehydration. In addition, affected
children did not suffer from neurologic impairment.
These findings are in accordance with most but not all of
the recent reports of FRG with identified SGLT2 muta-
tions. In their report on glucosuria with significant neuro-
logical involvement, van den Heuvel et al [12] postulated
that the central nervous system symptoms of the affected
child might have resulted from the SGLT2 impairment.
Based on the phenotypes of our patients as well as on
the clinical features in all other individuals reported to
date with SGLT2 mutations, we suggest that FRG is gen-
erally an asymptomatic disorder, and that the neurologic
impairment of the child with FRG described by van den
Heuvel et al [12] may be a coincidental finding, probably
bearing no relation to the SGLT2 mutation, and possibly
resulting from a separate mutation in this consanguineous
marriage, or from an unrelated nonhereditary cause.
A unique phenotypic feature in the patients pre-
sented in the current study is the presence of gen-
eralized aminoaciduria. Biochemical investigation in
these patients excluded other disorders known to cause
aminoaciduria such as generalized proximal tubulopathy
or vitamin D deficiency. Aminoaciduria has been previ-
ously described in FRG [16–18], but even in these reports
the aminoaciduria was selective. Our patients show a gen-
eralized pattern of aminoaciduria, with no predilection
toward overexcretion of specific amino acid subgroups.
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Assuming that at least some of the previously described
cases of FRG with aminoaciduria also harbor, an as yet
unidentified, SGLT2 mutation, the basis for the differ-
ence in the pattern of aminoaciduria between our patients
and those in previous reports is unclear.
Aminoaciduria has not been described in any of the
recently published cases with SGLT2 mutations. In the
reports of van den Heuvel et al [12] and Calado et al [13]
it was specifically indicated that aminoaciduria was tested
for and excluded in their patients. Santer et al [4], how-
ever, have only generally stated that no proximal tubu-
lar dysfunction was found in affected individuals. Since
neither the types of measured urinary amino acids, nor
the methods by which these measurements were per-
formed were specified in these reports, a technical or
methodologic basis for the differences in the presence of
aminoaciduria in patients with FRG cannot be excluded
with certainty.
Renal glucosuria accompanied by generalized
aminoaciduria also is a feature of maturity-onset dia-
betes of young age type 3 (MODY3) [26]. MODY3 is
an inherited disorder resulting from a mutation in the
hepatocyte nuclear factor-1 alpha (HNF-1a) gene, whose
protein product acts as a regulator of transcription for
SLC5A2 [27]. MODY3 patients suffer from a defect in
tubular glucose transport due to reduced SGLT2 expres-
sion, which leads to a lower renal threshold for glucose
excretion [28]. Bingham et al [29] have shown that
generalized aminoaciduria was not exclusively present
in MODY3, but was rather a feature of all patients
with diabetes mellitus. They have found the degree of
aminoaciduria in all types of diabetes to be positively
correlated with the severity of glucosuria, and concluded
that the aminoaciduria in all types of diabetes was a
consequence of glucosuria. It should be noted, however,
that impaired renal amino acid reclamation in diabetes
mellitus in general can be a result of diabetes-related
changes in levels of hormones known to affect amino
acid transport [30]. Furthermore, at least in MODY3,
the aminoaciduria can be caused by a direct effect of
the mutation in the HNF-1a gene on the expression and
activity of amino acid transporters.
The cellular and molecular mechanisms underlying the
aminoaciduria observed in our patients, bearing the mis-
sense mutation in the SGLT2 gene, are unknown. The in-
vestigation of amino acid transport pathways in the renal
tubular epithelium has delineated several transport sys-
tems [30–32]. These systems include various electrogenic
and electroneutral, Na+-dependent (concentrative) and
Na+-independent, cotransport, antiport, and uniport (fa-
cilitated diffusion) systems, for acidic, dibasic, and neu-
tral amino acids, that reside in the luminal or basolateral
membrane of proximal tubular cells [30]. Net transep-
ithelial flux of amino acids is composed of transcellular
amino acid transport in both directions, namely lumen
to interstitium and interstitium to lumen. Interstitium to
lumen oriented backflux through paracellular pathways
also occurs. This complex array of amino acid transport
pathways is modulated by various intracellular and extra-
cellular, hormonal and nonhormonal, adaptive and reg-
ulatory factors [30–32]. A derangement in any of these
transport systems or regulatory mechanisms can result in
aminoaciduria.
Although generalized aminoaciduria is apparently a
unique phenotypic feature in FRG subjects bearing the
K321R mutation, the remote possibility that impaired
tubular amino acid reabsorption is a direct consequence
of an SLC5A2 mutation per se seems highly unlikely.
First, there is no known direct relation between SGLT2
function and tubular amino acid transport mechanisms.
Second, it is not reasonable to relate such nonspecific
aminoaciduria, involving simultaneous impairment of
multiple amino acid transport systems, to SGLT2 dys-
function.
The aminoaciduria in patients with SLC5A2 muta-
tion is most likely a consequence of the impaired proxi-
mal tubular glucose reabsorption. The exact role of the
aberrant glucose reabsorption in the pathogenesis of
aminoaciduria is a subject for future research. It remains
to be determined whether this effect is mediated, for
example, by changes in Na+ coupling of amino acid trans-
porters, voltage-related changes, reduction in intracellu-
lar energy available for amino acid transport, aberrations
in intracellular signal transduction pathways controlling
amino acid transport, increased intraluminal glucose-
related osmotic forces, or any other potential derange-
ments in tubular amino acid transport.
CONCLUSION
FRG secondary to the novel SGLT2 missense muta-
tion K321R is inherited as an autosomal-recessive trait.
The location of the mutation suggests an important role
for the eighth transmembrane domain in sugar transport.
Affected individuals are asymptomatic, although they ex-
hibit extreme levels of glucosuria accompanied by gener-
alized aminoaciduria. We suggest that the aminoaciduria
observed in FRG is a consequence of the impairment in
tubular glucose reabsorption. The mechanism whereby
the K321R mutation severely impairs SGLT2 function,
as well as the exact role of the aberrant glucose reclama-
tion in the pathogenesis of aminoaciduria are subjects for
future research.
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